Skip to main content

Does Soliqua cause weight gain?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Sep 9, 2024.

Official Answer by Drugs.com

Weight gain is not a common side effect for Soliqua (insulin glargine and lixisenatide). In some clinical studies, patients using Soliqua had an average weight loss of 0.1 and 0.3 kg (0.2 and 0.7 lb). In contrast, patients using only insulin glargine had a weight gain of 1.1 and 2 kg (2.6 and 4.4 lb).

Clinical studies and weight loss with Soliqua 100/33

Studies have shown that the use of Soliqua 100/33 may help to reduce the amount of weight gained when compared to using insulin glargine alone.

In one 30-week research study called the LixiLan-O study, insulin glargine/lixisenatide (the two components of Soliqua) was compared with both components individually, insulin glargine (Lantus) and lixisenatide (Adlyxin), given separately.

In a subgroup analysis of the LixiLan-O study, researchers looked at patients with a high A1C of at least 9%.

Another subgroup analysis of the LixiLan-O study looked at patients whose type 2 diabetes was uncontrolled when using two oral agents.

In the LixiLan-L study, insulin glargine/lixisenatide (the components of Soliqua) was compared to insulin glargine in patients with type 2 diabetes who were not controlled on basal insulin and oral glucose-lowering agents.

Related questions

Bottom Line

This is not all the information you need to know about Soliqua 100/33 for safe and effective use. Review the full Soliqua 100/33 information here, and discuss this information with your doctor or other health care provider.

References
  • Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial [published correction appears in Diabetes Care. 2017 Jun;40(6):809]. Diabetes Care. 2016;39(11):2026-2035. doi:10.2337/dc16-0917
  • Davies MJ, Russell-Jones D, Barber TM, et al. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Diabetes Obes Metab. 2019;21(8):1967-1972. doi:10.1111/dom.13791
  • Aroda V, Rosenstock J, Wysham C, et al. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016 Nov; 39(11): 1972-1980. https://doi.org/10.2337/dc16-1495
  • Soliqua 100/33 [product information]. Nov. 2019. Sanofi-Aventis U.S. LLC Bridgewater, NJ. Accessed September 17, 2020 at http://products.sanofi.us/soliqua100-33/Soliqua100-33.pdf

Read next

Does Soliqua come with pen needles?

No, the pen needles are not included in your box of Soliqua, you will need to buy them separately. If you are not sure which needles to use, ask your doctor or pharmacist before you buy them. You should only use needles that are compatible with your Soliqua 100/33 prefilled pen. Continue reading

How long does it take for Soliqua to work?

Soliqua 100/33 is a combination of insulin glargine, a long-acting insulin, and lixisenatide, a GLP-1 receptor agonist. Soliqua starts to lower levels of glucose (sugar) in the blood two hours after injection and keeps working evenly for 20 to 24 hours in most patients. Continue reading

How many units are in a Soliqua pen?

The Soliqua 100/33 pen injector contains 100 units of insulin glargine per one milliliter (mL). It also contains 33 mcg of lixisenatide per mL. Each Soliqua pen holds a total of 3 mL, so there is a total of 300 units of insulin glargine per pen. The maximum dose of Soliqua 100/33 is 60 units daily. Continue reading

See also:

Related medical questions

Drug information

Related support groups